Adjuvant docetaxel for node-positive breast cancer
Adjuvant docetaxel for node-positive breast cancer
复制标题
DOI：
10.1056/nejmoa043681
复制
发表时间：
2005-06-02
影响因子：
158.5
通讯作者：
Vogel, C
中科院分区：
文献类型：
--
作者：
Martin, M;Pienkowski, T;Vogel, C
背景：我们比较了多西他赛加多柔比星和环磷酰胺（TAC）与氟尿嘧啶加多柔比星和环磷酰胺（FAC）作为可手术淋巴结阳性乳腺癌的辅助化疗。方法：我们将1491例腋窝淋巴结阳性乳腺癌患者随机分为6个周期，手术后使用TAC或FAC作为辅助化疗。主要终点是无病生存率。结果：在中位随访55个月时，在随机分配接受TAC的745名患者中，5年无病生存率估计为75%，在随机分配接受FAC的746名患者中，估计为68%，表明TAC组复发风险降低28%（P=0.001）。五年的总生存率估计分别为87%和81%。TAC治疗导致死亡风险降低30%（P=0.008）。TAC组3 ~ 4级中性粒细胞减少发生率为65.5%，FAC组为49.3%（P
BACKGROUND:We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer.METHODS:We randomly assigned 1491 women with axillary node-positive breast cancer to six cycles of treatment with either TAC or FAC as adjuvant chemotherapy after surgery. The primary end point was disease-free survival.RESULTS:At a median follow-up of 55 months, the estimated rates of disease-free survival at five years were 75 percent among the 745 patients randomly assigned to receive TAC and 68 percent among the 746 randomly assigned to receive FAC, representing a 28 percent reduction in the risk of relapse (P=0.001) in the TAC group. The estimated rates of overall survival at five years were 87 percent and 81 percent, respectively. Treatment with TAC resulted in a 30 percent reduction in the risk of death (P=0.008). The incidence of grade 3 or 4 neutropenia was 65.5 percent in the TAC group and 49.3 percent in the FAC group (P